Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Lercanidipine | Lercadip | 4.4 Special warnings A185:C185and precautions for use | Sick-sinus syndrome, | Mar,2024 |
| Etanercept | Enbrel | 4.8 Undesirable effects | Glomerulon ephritis | Mar,2024 |
| Pantoprazole | Pantozol | "4.3 Contraindications 4.4 Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction" | "Co-administer Rilpivirine Gastric malignancy, Sub-acute cutaneous lupus erythematosus HIV protease inhibitors " | Feb,2024 |
| Cyclophosphamide | Endoxan | "4.4. Special warnings and precautions for use 4.5 Interaction with other medicinal products and other forms of interaction 4.6 Fertility, pregnancy and lactation" | "Dose adjustment due to myelosuppression is recommended , Men treated with cyclophosphamide should be informed about sperm preservation prior to treatment Clozapine, CYP2B6 and CYP3A4 inhibitors, Grapefruit Contraception in males and females" | Feb,2024 |
| Pilocarpine Hydrochloride | Apicarpine | 4.6 Fertility, pregnancy and lactation | Human and animal data | Feb,2024 |
| Hydroxyurea | CureamL | "4.4. Special warnings and precautions for use 4.6. Fertility, pregnancy and lactation 4.8. Undesirable effects" | "Bone Marrow , Anaemia, HIV , cancer Azoo- or oligospermia, sometimes reversible, have been observed in men. Male patient should be informed about the possibility of sperm conservation before the start of therapy. hydroxyurea may be genotoxic. Men under therapy are advised to use effective contraceptive Hypersensitivity, Drug induced fever, Tumour lysis syndrome" | Jan,2024 |